CIBC Asset Management Inc grew its position in Laboratory Corporation of America Holdings (NYSE:LH) by 3.0% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 13,726 shares of the medical research company’s stock after purchasing an additional 397 shares during the period. CIBC Asset Management Inc’s holdings in Laboratory Corporation of America Holdings were worth $2,072,000 as of its most recent filing with the SEC.

Other large investors have also recently modified their holdings of the company. Acrospire Investment Management LLC boosted its stake in shares of Laboratory Corporation of America Holdings by 16.5% in the 2nd quarter. Acrospire Investment Management LLC now owns 705 shares of the medical research company’s stock valued at $109,000 after purchasing an additional 100 shares in the last quarter. Sun Life Financial INC boosted its stake in shares of Laboratory Corporation of America Holdings by 9,200.0% in the 2nd quarter. Sun Life Financial INC now owns 744 shares of the medical research company’s stock valued at $115,000 after purchasing an additional 736 shares in the last quarter. IFP Advisors Inc boosted its stake in shares of Laboratory Corporation of America Holdings by 83.9% in the 2nd quarter. IFP Advisors Inc now owns 1,146 shares of the medical research company’s stock valued at $177,000 after purchasing an additional 523 shares in the last quarter. Hourglass Capital LLC acquired a new stake in shares of Laboratory Corporation of America Holdings in the 2nd quarter valued at $200,000. Finally, Institute for Wealth Management LLC. acquired a new stake in shares of Laboratory Corporation of America Holdings in the 2nd quarter valued at $220,000. Institutional investors own 93.54% of the company’s stock.

In other Laboratory Corporation of America Holdings news, Director Dwight Gary Gilliland sold 971 shares of the business’s stock in a transaction dated Monday, October 30th. The stock was sold at an average price of $153.52, for a total transaction of $149,067.92. Following the completion of the sale, the director now directly owns 3,501 shares of the company’s stock, valued at approximately $537,473.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO David P. King sold 132,713 shares of the business’s stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $157.06, for a total value of $20,843,903.78. The disclosure for this sale can be found here. Insiders have sold a total of 209,871 shares of company stock valued at $32,892,005 over the last three months. Company insiders own 0.90% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another site, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be accessed at https://www.watchlistnews.com/laboratory-corporation-of-america-holdings-lh-stake-raised-by-cibc-asset-management-inc/1711830.html.

Shares of Laboratory Corporation of America Holdings (NYSE LH) opened at $150.36 on Friday. The firm has a market capitalization of $15,470.00, a PE ratio of 16.12, a price-to-earnings-growth ratio of 1.59 and a beta of 0.87. Laboratory Corporation of America Holdings has a twelve month low of $123.36 and a twelve month high of $164.22. The company has a current ratio of 1.89, a quick ratio of 1.75 and a debt-to-equity ratio of 1.18.

Laboratory Corporation of America Holdings (NYSE:LH) last announced its quarterly earnings data on Wednesday, October 25th. The medical research company reported $2.46 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.38 by $0.08. The firm had revenue of $2.60 billion during the quarter, compared to analysts’ expectations of $2.55 billion. Laboratory Corporation of America Holdings had a return on equity of 16.75% and a net margin of 7.40%. The company’s quarterly revenue was up 9.5% compared to the same quarter last year. During the same period in the previous year, the business posted $2.25 EPS. equities analysts anticipate that Laboratory Corporation of America Holdings will post 9.53 earnings per share for the current fiscal year.

Several equities research analysts have recently commented on LH shares. Craig Hallum restated a “buy” rating and issued a $179.00 target price (up previously from $157.00) on shares of Laboratory Corporation of America Holdings in a research note on Thursday, July 27th. Zacks Investment Research upgraded shares of Laboratory Corporation of America Holdings from a “sell” rating to a “hold” rating in a research note on Thursday, July 27th. Barclays PLC boosted their target price on shares of Laboratory Corporation of America Holdings from $182.00 to $183.00 and gave the company an “overweight” rating in a research note on Thursday, July 27th. Morgan Stanley boosted their target price on shares of Laboratory Corporation of America Holdings from $154.00 to $166.00 and gave the company an “overweight” rating in a research note on Thursday, August 10th. Finally, ValuEngine upgraded shares of Laboratory Corporation of America Holdings from a “hold” rating to a “buy” rating in a research note on Wednesday, September 6th. Seven analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $169.00.

About Laboratory Corporation of America Holdings

Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

Institutional Ownership by Quarter for Laboratory Corporation of America Holdings (NYSE:LH)

Receive News & Ratings for Laboratory Corporation of America Holdings Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corporation of America Holdings and related companies with Analyst Ratings Network's FREE daily email newsletter.